Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Inclusion Criteria: 1. Age ≥18 years old, male or female 2. Life expectancy≥12 weeks; 3. Phase 1b: Patients with advanced solid tumors diagnosed by histology or cytology, who have been failure to previous standard treatments; Phase 2: Patients with HNSCC, NPC, OC, NSCLC, SCLC, HCC, cHL and other solid tumors diagnosed by histology or cytology, who have been failure to first-line standard treatment (including PD-1/L1) at least; 4. ECOG PS of 0 or 1; 5. Adequate organs function, including bone marrow, hepatic, renal, cardiac, coagulation. 6. Adverse events associated with previous anti-tumor therapy have returned to≤ grade 1(NCI CTCAE V5.0); Exclusion Criteria: 1. Previous treatment with CD47 inhibitor/SIRPαinhibitor or fusion protein; 2. Patients with symptomatic or progressive central nervous system (CNS) metastasis; 3. Uncontrolled hypertension, pulmonary hypertension or unstable angina, myocardial infarction within 6 months prior to administration; a history of chronic heart failure (NYHA G3/4); severe arrhythmia; 4. A history of arterial thrombosis, deep venous thrombosis and pulmonary embolism within 3 months prior to administration; 5. A history of moderate or severe dyspnea, interstitial lung disease (ILD) or servre pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency; 6. With other malignant tumors; 7. Diseases that may cause gastrointestinal bleeding or perforation; 8. Uncontrollable pleural, peritoneal or pericardial effusions; 9. A history of immunodeficiency; 10. A history of autoimmune diseases; 11. Uncontrolled severe active infections.